Brokerage firm analysts are predicting that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will grow at an accelerated rate over the next five years. Sell-side analysts are looking for the company to grow 195.40% over the next year and 38.00% over the next five years.
Conatus Pharmaceuticals Inc.’s trailing 12- months EPS is -0.82. Last year, their EPS growth was -1.20% and their EPS growth over the past five years was 35.60%.
Let’s start off by taking a look at how the stock has been performing recently. Over the past twelve months, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s stock was -22.58%. Last week, it was -4.23%, -19.37% over the last quarter, and -27.40% for the past half-year.
Over the past 50 days, Conatus Pharmaceuticals Inc. stock was -35.33% off of the high and 3.98% removed from the low. Their 52-Week High and Low are noted here. -56.91% (High), 134.24%, (Low).
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s performance this year to date is -22.58%. The stock has performed -4.23% over the last seven days, -22.58% over the last thirty, and -19.37% over the last three months. Over the last six months, Conatus Pharmaceuticals Inc.’s stock has been -27.40% and 99.02% for the year.
Wall Street analysts are have a consensus analyst recommendation of 1.80 on the stock. This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Brokerages covering the name have a $17.25 on the stock.
The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.